trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim
Cholesterol levels can be lowered too much, causing adverse health effects
the verdict
CONTESTED
the evidence cuts both ways
confidence 23/100

While major clinical guidelines endorse aggressive lipid-lowering strategies as safe and effective for cardiovascular prevention, some emerging studies raise concerns that overly low cholesterol levels may be linked to adverse effects such as bleeding risks or metabolic changes.

The evidence we hold leans leans refuted

How this was weighed

official record 3x · fact-check 2x · hedged 1x · crowd & reference 1x

  • Low LDL-Cholesterol and Hemorrhagic Risk: Mechanistic Insigh · peer-reviewed · supports · weight 1.05 · 2025
  • Emerging risks of lipid-lowering therapy and low LDL levels: · peer-reviewed · supports · weight 1.05 · 2025
  • Lipid-Lowering Therapy after Acute Coronary Syndrome · peer-reviewed · refutes · weight 1.3 · 2024
  • Benefits of intensive lipid-lowering therapies in patients w · peer-reviewed · refutes · weight 1.05 · 2024
  • Lipid management in type 2 diabetes and non-HDL-cholesterol: · peer-reviewed · refutes · weight 1.05 · 2026
Evidence for · 2
Low LDL-Cholesterol and Hemorrhagic Risk: Mechanistic Insights and Clinical Perspectives.
2025 · cited by 4
Paper [3] highlights emerging clinical concerns regarding very low LDL-C levels and an increased risk of bleeding, such as hemorrhagic stroke.
Evidence against · 3
Lipid-Lowering Therapy after Acute Coronary Syndrome
2024 · cited by 24
Paper [0] supports the 'lower is better' strategy and demonstrates the safety and efficacy of intensive lipid-lowering therapy post-acute coronary syndrome.
See more details
More for · 1
Emerging risks of lipid-lowering therapy and low LDL levels: implications for eye, brain, and new-onset diabetes.
2025 · cited by 4
Paper [4] notes that excessively low LDL-C can have unintended health consequences, including potential links to increased glaucoma risk and new-onset diabetes.
More against · 2
Benefits of intensive lipid-lowering therapies in patients with acute coronary syndrome: a systematic review and meta-analysis
2024 · cited by 7
Paper [1] shows that intensive lipid-lowering therapies reduce major cardiovascular events without increasing all-cause or cardiovascular mortality.
Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.
2026 · cited by 1
Paper [10] confirms that lipid-lowering therapies effectively reduce LDL-C and cardiovascular risk in high-risk patients following clinical guidelines.
The paper trail · every fact has a biography
first checked02 Aug 2026
judged → CONTESTED · 2302 Aug 2026
This receipt carries no identity, shared or not. Sharing publishes your connection to it, not your data.
Check your own claim
Challenge the receipt
trust me, bro: win the argument, pass the class, survive peer review.
This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt